NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $139.88 -3.50 (-2.44%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$135.95▼$144.0050-Day Range$138.43▼$176.1152-Week Range$36.42▼$177.37Volume1.54 million shsAverage Volume666,072 shsMarket Capitalization$4.67 billionP/E RatioN/ADividend YieldN/APrice Target$171.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get TransMedics Group alerts: Email Address TransMedics Group MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside22.6% Upside$171.44 Price TargetShort InterestBearish18.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 11 Articles This WeekInsider TradingSelling Shares$9.55 M Sold Last QuarterProj. Earnings Growth51.24%From $1.21 to $1.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.92 out of 5 starsMedical Sector351st out of 910 stocksElectromedical Equipment Industry8th out of 22 stocks 3.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTransMedics Group has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.17% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in TransMedics Group has recently increased by 5.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 3.1 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for TransMedics Group this week, compared to 6 articles on an average week.Search Interest18 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows15 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 36% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,551,089.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow by 51.24% in the coming year, from $1.21 to $1.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -411.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -411.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 24.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About TransMedics Group Stock (NASDAQ:TMDX)TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More TMDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Stock News HeadlinesAugust 30, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $1,760,200.00 in StockAugust 11, 2024 | insidertrades.comAnil P. Ranganath Sells 703 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 9, 2024 | insidertrades.comTransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $1,012,230.00 in StockSeptember 5 at 11:59 PM | msn.comTransMedics Stock Plunges Post-Q3 ResultsSeptember 5 at 4:50 PM | fool.comWhy Shares of TransMedics Stock Plunged This WeekSeptember 5 at 1:57 PM | markets.businessinsider.comTransMedics Group: A Strong Buy on Steady Transplant Volume Growth and Market PotentialSeptember 4 at 5:49 PM | markets.businessinsider.comTransMedics Group (TMDX) Receives a Buy from Piper SandlerSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 3, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for TransMedics Group (TMDX)September 1, 2024 | americanbankingnews.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $1,760,200.00 in StockAugust 28, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Now Covered by Analysts at Needham & Company LLCAugust 27, 2024 | msn.comTransMedics Group, Inc. (TMDX): One of Oppenheimer’s Top Stock Picks For the Next 12 MonthsAugust 26, 2024 | markets.businessinsider.comTransMedics Group: A Strong Buy on Unique Positioning and Growth in the Organ Transplant MarketAugust 23, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on TransMedics Group (TMDX)August 22, 2024 | benzinga.comNavigating 10 Analyst Ratings For TransMedics GrAugust 22, 2024 | msn.comTransMedics wins bullish view at Needham on potential 2024 profitsAugust 22, 2024 | msn.comTransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% UpsideSee More Headlines Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$171.44 High Stock Price Target$208.00 Low Stock Price Target$127.00 Potential Upside/Downside+22.6%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E Ratio115.60 P/E GrowthN/ANet Income$-25,030,000.00 Net Margins0.84% Pretax Margin0.41% Return on Equity15.98% Return on Assets3.41% Debt Debt-to-Equity Ratio2.67 Current Ratio9.37 Quick Ratio8.48 Sales & Book Value Annual Sales$241.62 million Price / Sales19.31 Cash Flow$0.13 per share Price / Cash Flow1,060.72 Book Value$5.69 per share Price / Book24.58Miscellaneous Outstanding Shares33,360,000Free Float30,631,000Market Cap$4.67 billion OptionableOptionable Beta1.99 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Waleed H. Hassanein M.D. (Age 56)Founder, President, CEO & Director Comp: $1.82MMr. Stephen Gordon (Age 56)CFO, Treasurer & Secretary Comp: $909.62kMr. Nicholas Corcoran (Age 41)Senior Vice President of Supply Chain & Operations Comp: $812.07kMr. Anil RanganathSenior VP, General Counsel & Corporate SecretaryDr. Tamer I. Khayal M.D. (Age 55)Chief Commercial Officer Comp: $900.11kMr. Mark AndersonSenior Director of Technology DevelopmentMs. Susan GoodmanVice President of Human ResourcesMs. Miriam C. Provost Ph.D. (Age 63)Vice President of Global Regulatory Affairs Comp: $535.93kMore ExecutivesKey CompetitorsZynexNASDAQ:ZYXIFONARNASDAQ:FONRCuteraNASDAQ:CUTRSmith & NephewNYSE:SNNSolventumNYSE:SOLVView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 2,473 shares on 9/5/2024Ownership: 0.007%Nicholas CorcoranSold 10,000 sharesTotal: $1.76 M ($176.02/share)Dana Investment Advisors Inc.Sold 7,558 shares on 8/27/2024Ownership: 0.045%Teachers Retirement System of The State of KentuckyBought 2,790 shares on 8/26/2024Ownership: 0.008%Cetera Investment AdvisersSold 2,401 shares on 8/22/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $78.93 on January 1st, 2024. Since then, TMDX shares have increased by 77.2% and is now trading at $139.88. View the best growth stocks for 2024 here. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) issued its quarterly earnings results on Wednesday, July, 31st. The company reported $0.35 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.14. The company's revenue for the quarter was up 117.7% on a year-over-year basis. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? TransMedics Group's top institutional shareholders include Driehaus Capital Management LLC (4.51%), Mackenzie Financial Corp (1.84%), Allspring Global Investments Holdings LLC (1.73%) and Bank of New York Mellon Corp (1.28%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, David Weill, Anil P Ranganath, Edward M Basile, Stephanie Lovell, Laura Damme and Edwin M Kania Jr. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX) and Yamana Gold (AUY). This page (NASDAQ:TMDX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TMDX Stock Alerts